– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader – – Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader –

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ModivCare, Inc. ("ModivCare" or "the Company") (NASDAQ:MODV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ModivCare securities between November 3, 2022 and September 15, 2024, both dates inclusive (the "Class Period").

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced the publication of the manuscript titled “Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a Phase 3 Randomized Trial” in the Journal of Clinical and Translational Hepatology. This publication details the full protocol for the pivotal Phase 3 trial to support the use of hydronidone in Chinese patients with liver fibrosis associated with chronic hepatitis B (“CHB”).

PARIS, March 27, 2025 (GLOBE NEWSWIRE) -- WeRide (Nasdaq: WRD), a world leader in autonomous driving technology, announced that the company, in partnership with the leading French autonomous mobility network operator beti, has obtained France's Level-4 driverless public road testing and operating permit. This makes WeRide the first and only technology company worldwide to hold driverless permits across five countries: China, the UAE, Singapore, France, and the U.S. This remarkable milestone underscores WeRide's global leadership, demonstrating its unparalleled technological capability and adaptability to diverse regulatory frameworks, and unwavering commitment to safety, compliance, and scalability in autonomous mobility.

DENVER--(BUSINESS WIRE)--Veritone, Inc. (NASDAQ: VERI), a leader in building human-centered enterprise AI solutions, today announced details of its participation at the NAB 2025 show taking place April 5 to 9 in Las Vegas. Through demonstrations and industry conversations in booth W1455 in the Las Vegas Convention Center's West Hall, Veritone will showcase AI solutions and services that transform unstructured audio and video into searchable, monetizable and intelligent assets, empowering media.

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 A 50% …

BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND submission expected in the first half of 2026 With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027 SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and …

TORONTO--(BUSINESS WIRE)--Americas Gold and Silver Corporation (TSX: USA) (NYSE American: USAS) (“Americas” or the “Company”), a growing North American precious metals producer, reports consolidated financial and operational results for the year ended December 31, 2024. This earnings release should be read in conjunction with the Company's Management's Discussion and Analysis, Financial Statements and Notes to Financial Statements for the corresponding period, which have been posted on the Amer.

LAVAL, QC / ACCESS Newswire / March 27, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter financial results after market close on Wednesday, April 30, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m.

This purchase order is a follow on from a November 2024 $3.5 million order Further demands for additional sites expected later in the year TORONTO, ON / ACCESS Newswire / March 27, 2025 / Electrovaya Inc. ("Electrovaya" or the "Company") (NASDAQ:ELVA)(TSX:ELVA), a leading lithium-ion battery technology and manufacturing company, today announced it has received purchase orders through its OEM sales channel valued at approximately US$7.3 million. The batteries will be used by a leading Fortune 100 e-commerce company in the United States and Canada for powering material handling electric vehicles in multiple distribution centers.

2024 highlighted by revenue growth, sequential margin expansion and strong profitability Full year GAAP diluted EPS of $2.25; Full year non-GAAP diluted adjusted EPS of $2.30 exceeds full year non-GAAP EPS target of $1.92 Strong market acceptance and sales momentum for BKR 9000 multiband radio throughout 2024 WEST MELBOURNE, FL / ACCESS Newswire / March 27, 2025 / BK Technologies Corporation (NYSE American:BKTI) (the "Company," "BK Technologies") today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. The Company will host a conference call today, March 27, 2025, at 9:00 a.m.

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD). The study results did not demonstrate a meaningful difference in complete response (CR) or overal.

Lululemon earnings, US GDP forecast, and jobless claims data take center stage today, offering key insights for stock market sentiment and indices outlook.

After reaching a year-to-date (YTD) high of $5.22 on March 11 following key subsidy announcements, Nio stock (NYSE: NIO) went on to crash following a disappointing quarterly report.

MPTI, EAT and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 27, 2025.

DALLAS--(BUSINESS WIRE)--AECOM (NYSE: ACM), the trusted global infrastructure leader, today announced that it has been selected in a joint venture by the Civil Engineering and Development Department (CEDD) of the HKSAR Government for the design and construction of Package 3 of the First Phase Development of the New Territories North – San Tin / Lok Ma Chau Development Node. This project is a cornerstone of the Northern Metropolis, a major new development in Hong Kong that will support approxima.

Specific patterns often repeat in the stock market. For example, small, unprofitable companies that surge based on hype tend to give back their gains quickly.

CVX aims to expand hydrocarbon exploration on Crete, Greece, increasing energy prospects and boosting the country's role in Mediterranean energy security.

GREENWICH, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- XPO (NYSE: XPO), a leading provider of freight transportation in North America, today announced that its Board of Directors has authorized the repurchase of up to $750 million of XPO's common stock. The new repurchase plan replaces XPO's previous share repurchase plan, authorized in February 2019, which had $503 million remaining as of March 26, 2025.

NEW YORK--(BUSINESS WIRE)--New Fortress Energy Inc. (NASDAQ: NFE) (“NFE”) announced today that it has finalized a transaction with Excelerate Energy, Inc. (NYSE: EE) (“Excelerate”) to sell its assets and operations in Jamaica for $1.055 billion. Proceeds from the transaction will be used to reduce NFE's corporate debt and for general corporate purposes. This transaction is expected to close in the second quarter of 2025 and marks a key step in NFE's strategy to optimize its asset portfolio and.